After Investing, GSK to Buy Out Celiac Drug Developer Sitari Pharma

GlaxoSmithKline is acquiring a startup it helped launch in 2013 as part of an alliance with life sciences venture capital firm Avalon Ventures. Avalon said Tuesday that GSK (NYSE: GSK) has agreed to buy the company, Sitari Pharmaceuticals, which has been developing a treatment for celiac disease. Sitari was the first of eight companies spun [?]